Alopecia areata
Conditions
Interventions
Combination group:In addition to oral baricitinib tablets (4 mg once daily), 5% minoxidil foam was topically applied to the entire alopecic area twice daily (1 g per application).
Control group:Received oral baricitinib tablets (4 mg once daily).
Sponsors
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years, both sexes; 2. Met diagnostic criteria for alopecia areata; 3. Severe alopecia areata with SALT (Severity of Alopecia Tool) score >=50; 4. Completed 6-month regular follow-up; 5. Treatment-naive or refractory to prior therapies; 6. Voluntarily participated with signed informed consent after full comprehension of the study.
Exclusion criteria
Exclusion criteria: 1. Women planning pregnancy, pregnant, or breastfeeding; 2. Active or suspected local scalp infections; 3. Hair loss attributed to genetic factors, infections, endocrine disorders, medications, or other non-alopecia areata etiologies; 4. Reduced neutrophils, lymphocytes, or hemoglobin on complete blood count (CBC); 5. Comorbid severe systemic diseases (e.g., organ dysfunction, infectious/communicable diseases, autoimmune diseases, cardiovascular diseases, thrombotic disorders, malignancies); 6. Hypersensitivity to the study medications; 7. Use of any alternative alopecia areata treatments during follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The severity of alopecia areata;Presence of anxiety and depression;Hair count;Hair density; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hair diameter;Follicular unit;Morphology of skin lesions; | — |
Countries
China
Contacts
Public ContactYong Zhang
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed